Cardiometabolic & kidneyResearch article
Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease
- analysis of Veterans with atherosclerotic cardiovascular disease (ASCVD) and chronic kidney disease (CKD) with high-sensitivity C-reactive protein (hsCRP) testing
Authors' conclusion
Among Veterans with ASCVD and CKD, SI was associated with an increased risk of MACE and higher health care utilization and costs.
Study context
- Population
- Veterans with ASCVD and CKD with hsCRP testing between 2008 and 2022
- Comparison
- Veterans with systemic inflammation (SI) vs without SI
- SIn = 39,006
- Outcome
- 3-point major adverse cardiovascular event (MACE) composite:
- Death
- Myocardial infarction
- Stroke
- Follow-up
- Median 4.2 years (IQR: 2.1-7.0)
Main finding
As reported in the abstract
Hazard ratio
1.40
95% CI 1.36–1.43
By group
SI vs without SI
HR 1.40 (95% CI 1.36–1.43)
Further findings
| Outcome | IRR (95% CI) | |
|---|---|---|
| Hospitalizations | 1.24 (1.20–1.29) | |
| 0.512Incidence rate ratio (log scale) |
Age
Peripheral arterial disease prevalence
- Age: P < 0.001
- Peripheral arterial disease prevalence: P < 0.001
Additional health care costs · 1 year
- Additional costs with SI
- $4,115 (95% CI: $1,878-$6,353)
Original publication
Systemic Inflammation and Adverse Outcomes in Patients With Atherosclerotic Cardiovascular Disease and Chronic Kidney Disease. JACC Adv. Published 22 April 2026. doi:10.1016/j.jacadv.2026.102765
Summarised from the published abstract; every number is checked against it